"But at the time, his skepticism represented a familiar story: Bold, visionary ideas are met with resistance and fear from industries entrenched in conventional wisdom. Yet, time and again, we've seen how disruptors use technology and sheer conviction to rewrite the rules and yield transformative outcomes. In the last decade alone, this played out across industries like transportation, aerospace, and defense-from electric vehicles challenging Detroit to reusable rockets shattering the assumption of expendable space travel."
"The antidote to this paralysis isn't less ambition, but more-a renewed focus on the first-principles mindset that defines truly transformative companies and has the potential to reduce our industry's abysmal 90% failure rate. The reality is no other industry has more profound potential to radically improve lives. Today, the convergence of AI and automation with biology and chemistry is a multitrillion-dollar opportunity to fundamentally reinvent the way we make new medicines. The potential impact is extraordinary for everyone who eventually becomes a patient."
Bold, visionary ideas often face resistance from entrenched industries, causing skepticism that can mask future transformative change. Disruptors repeatedly use technology and conviction to rewrite rules, as seen in electric vehicles and reusable rockets. The pharmaceutical industry exhibits cautious incrementalism, prioritizing payer and pharmacy benefit manager concerns over ambitious experimentation. A first-principles mindset combined with AI, automation, biology, and chemistry convergence creates a multitrillion-dollar opportunity to reinvent medicine discovery and manufacturing. Greater ambition could reduce the industry's roughly 90% failure rate and deliver extraordinary patient benefits by accelerating the development of fundamentally new medicines.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]